Op-Ed: It's time for the greater Houston area to embrace connectivity

guest column

Every stakeholder should be at the table: industry, city officials, businesses, and most importantly, the local community, to support the expansion of the local 5G network. Photo via Getty Images

We live in a digital first world where the need for fast, reliable connectivity is not just something people want--it’s a necessity.

Connectivity plays a key role in every facet of life from economic development to public safety. Tomorrow’s innovations will rely on today’s infrastructure. That means cities and states must keep their eyes and efforts firmly fixed on the most up-to-date technology and prepare for modern wireless services, including 5G technology, the fifth-generation wireless system, in order to stay ahead of the curve.

Many of us have seen television commercials and internet ads touting the benefits 5G will bring, particularly as it relates to speed and reliability. But 5G is much more than speed. It will pave the way for innovation across a broad range of industries, injecting trillions into the global economy and ultimately changing the way we work, get around the city and live our lives. 5G connectivity will be able to process mass amounts of data with little to no latency, a requirement for the technology of tomorrow.

The economic impact will also be significant. A report from Accenture found that 5G will greatly benefit the Texas economy in the next five years, bringing Texas an estimated $235.8 billion in additional sales, $130.5B in new GDP and 1.35M in potential jobs.

Cities that embrace this coming technological boom will find themselves better prepared to tackle challenges and address the needs of their residents. Take public safety for example: 80 percent of 911 calls originate from mobile devices, which rely on a network of infrastructure – towers, small cells and fiber. 5G will enable seamless data transfer between first responders and dispatchers, including the exact location of a call as well as medical history to EMS. It will create a seamless network to properly communicate to other emergency services like fire and police departments. An estimated 10,000 lives could be saved each year if emergency response times were reduced by one minute.

Relevant to Pasadena are the transformations 5G will bring to healthcare and manufacturing. 5G is revolutionizing advanced training for medical professionals and allows more remote post-acute care and home-based models as well as enhanced communication between medical professionals. This will ultimately drive better patient outcomes and cost savings greater than 30 percent. 5G will also increase capacity and security for Pasadena’s wide variety of manufacturers, from chemicals to electronics to food and textiles, as well as create safer, smarter and more efficient processes that will drive continued innovation.

The full potential of 5G requires communications infrastructure–towers, small cells and fiber—and modernized regulations from local and state governments. Without the right infrastructure and policies in place, communities in Texas - like Pasadena - won’t have access to the innovative technology and benefits that 5G will embolden.

Research has found that 78 percent of Texans support their city leadership taking faster action to implement 5G technology. Yet Pasadena city officials have spent countless hours and financial resources since September 2020 fighting a lawsuit to prevent 5G installations in this community. Those dollars could have been spent on real community needs like infrastructure, utilities and public works. Pasadena is now behind its peers across the greater Houston area, where we have witnessed thousands of successful deployments of this necessary communications infrastructure. This puts Pasadena at a disadvantage as a great place to do business and improve the lives of residents.

It’s time for Pasadena to embrace the smart city infrastructure of the future. Other Texas cities like in Houston, Dallas and San Antonio, or even neighboring La Porte, have initiated smart policies that have encouraged connectivity in their communities as well as investments from industry. Unfortunately, Pasadena’s connectivity and infrastructure are being impeded by local politics. Every stakeholder should be at the table: industry, city officials, businesses, and most importantly, the local community, to support the expansion of the local 5G network.

------

Scott Dunaway is a spokesperson for the Texas 5G Alliance.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.

View All Listings